Search Results - Suzanne Lentzsch

Refine Results
  1. 1
    Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

    Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis by Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, Meera Mohan, Suzanne Lentzsch, Anita D’Souza

    Published 2023
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  2. 2
    Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

    Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells by Suzanne Lentzsch, Margarete Gries, Martin Janz, Ralf C. Bargou, Bernd Dörken, Markus Y. Mapara

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage

    The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage by Rentian Feng, Ana B. Oton, Markus Y. Mapara, Gülsüm Anderson, Chandra P. Belani, Suzanne Lentzsch

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1

    Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves... by Corinna Leng, Margarethe Gries, Judy Ziegler, Anna Lokshin, Paolo Mascagni, Suzanne Lentzsch, Markus Y. Mapara

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

    Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation by Guoshuang Xu, Kai Liu, Judy M. Anderson, Kenneth D. Patrene, Suzanne Lentzsch, G. David Roodman, Hongjiao Ouyang

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice

    Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice by Huihui Ma, Caisheng Lu, Judith Ziegler, Ailing Liu, Antonia R. Sepulveda, Hideho Okada, Suzanne Lentzsch, Markus Y. Mapara

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM

    IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM by Shirong Li, Rekha Pal, Sara A. Monaghan, Peter Schäfer, Hongjiao Ouyang, Markus Y. Mapara, Deborah L. Galson, Suzanne Lentzsch

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway

    In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway by Manik Chatterjee, Dirk Hönemann, Suzanne Lentzsch, Kurt Bommert, Christine Sers, Pia Herrmann, Stephan Mathas, Bernd Dörken, Ralf C. Bargou

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study by Suzanne Lentzsch, Galina Lagos, Raymond L. Comenzo, Jeffrey A. Zonder, Keren Osman, Samuel Pan, Divaya Bhutani, Silva Pregja, Vaishali Sanchorawala, Heather Landau

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease

    The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease by Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Gabriel M. Pagnotti, Lewis M. Brown, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

    Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia by Kenneth A. Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley M. Marks, Diana Lenzner, L. Pietragallo, M. Sulecki, Ahmad A. Tarhini, Michael Boyiadzis

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

    Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis by Camille V. Edwards, Nisha Rao, Divaya Bhutani, Markus Y. Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

    Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia by Rekha Pal, Sara A. Monaghan, Andrea Cortese Hassett, Markus Y. Mapara, Peter Schäfer, G. David Roodman, Margaret V. Ragni, Lynn C. Moscinski, Alan F. List, Suzanne Lentzsch

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells

    C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells by Rekha Pal, Martin Janz, Deborah L. Galson, Margarete Gries, Shirong Li, Korinna Jöhrens, Ioannis Anagnostopoulos, Bernd Dörken, Markus Y. Mapara, Lisa Borghesi, Lela Kardava, G. David Roodman, Christine Milcarek, Suzanne Lentzsch

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Diffuse Lung Involvement as a Rare Presentation of Systemic AL Amyloidosis: A Retrospective Cohort Study

    Diffuse Lung Involvement as a Rare Presentation of Systemic AL Amyloidosis: A Retrospective Cohort Study by Amy Song, George Mellgard, Claudia Bellofiore, Marco Basset, Mario Nuvolone, Andrea Foli, Giampaolo Merlini, Matthew J. Maurer, Markus Y. Mapara, Divaya Bhutani, Suzanne Lentzsch, Hiram Shaish, Giovanni Palladini, Rajshekhar Chakraborty, Paolo Milani

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease

    Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease by Jing Fu, Shirong Li, Rentian Feng, Huihui Ma, Farideh Sabeh, G. David Roodman, Ji Wang, Samuel T. Robinson, X. Edward Guo, Thomas Lund, Daniel P. Normolle, Markus Y. Mapara, Stephen J. Weiss, Suzanne Lentzsch

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

    Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 o... by Suzanne Lentzsch, Amy K. O’Sullivan, Ryan Kennedy, Mohammad Abbas, Lijun Dai, Silvana Pregja, Steve Burt, Michael Boyiadzis, G. David Roodman, Markus Y. Mapara, Mounzer Agha, John Waas, Yongli Shuai, Daniel P. Normolle, Jeffrey A. Zonder

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

    Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma by Jatin J. Shah, Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Christina L. Gomes, N G Pascucci, David Smith, Robert Z. Orlowski, Brian G.M. Durie

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

    Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone... by Lia A. Moulopoulos, Vassilis Koutoulidis, Jens Hillengaß, Elena Zamagni, Jesús Dámaso Aquerreta, Charles Roche, Suzanne Lentzsch, Philippe Moreau, Michèle Cavo, Jesús F. San Miguel, Meletios Α. Dimopoulos, S. Vincent Rajkumar, Brian G.M. Durie, Evangelos Terpos, Stefan Delorme

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

    Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy by Anjan Thakurta, Anita K. Gandhi, Michelle F. Waldman, Chad C. Bjorklund, Yuhong Ning, Derek Mendy, Peter Schäfer, Antonia López-Girona, Suzanne Lentzsch, Steve Schey, Yolanda Calle, Rajani Chelliah, Robert Z. Orlowski, Anup Madan, Hervé Avet‐Loiseau, Rajesh Chopra

    Published 2013
    Get full text Get full text
    Carta
    Save to List
    Saved in:

Search Tools: